M Pharmaceutical Inc.
CNSX : MQ
OTCQB : MPHMF
FRANKFURT : T3F2

M Pharmaceutical Inc.

November 17, 2015 10:14 ET

M Pharmaceutical's Trimeo Patent Allowed by Canadian Intellectual Property Office

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 17, 2015) - M Pharmaceutical, Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced that the Canadian Intellectual Property Office has allowed patent application 2,720,691, entitled "Bezoar-Forming Units for Weight Control" to be issued. This patent was filed on April 28, 2009 and will remain in force for 20 years from that date.

The patent claims cover the design, composition, and methods to use "bezoar-forming units" that are temporary and dissolvable. This patent is fundamental to the design of M Pharma's Trimeo capsules, currently under development for weight loss.

This Canadian patent covers substantially the same claims as in United States patent 9,066,877B2, previously issued in June 2015.

Matthew Lehman, the Company's Chief Executive Officer: "I am pleased to report that this patent will be issued in Canada. It is a key part of our intellectual property strategy to protect our investment in developing Trimeo for weight loss applications in major global markets."

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Contact Information